EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome

Marta Araujo-Castro iD, Irina Bancos iD, Mario Detomas iD, Martin Reincke iD, Mahdi Salehi, Haibo Lu, Barbara Altieri iD, Markus Kroiss, Matthias Oettle, Fernando Guerrero-Pérez, Felicia A Hanzu, Rogelio García-Centeno und 8 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag115 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Marta Araujo-Castro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid 28034, Spain. Hauptthemen laut MEDLINE: Cushing Syndrome, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Most of the patients included in the clinical trials and real-world studies with osilodrostat only include patients with adrenocorticotropic hormone dependent Cushing syndrome (CS), while data on the efficacy and safety of osilodrostat in patients with adrenal CS is scarce.

Objective

To assess the efficacy and safety of osilodrostat in adrenal CS.

Methods

International study of patients with adrenal CS: patients treated with osilodrostat at any time were enrolled in the safety evaluation and those treated for longer than 4 weeks, in the efficacy evaluation. Patients were classified as responders if they experienced a reduction in urinary free cortisol (UFC) >50% (complete responders when UFC levels were below the upper limit of normal [ULN] and partial responders if there was a reduction >50% but not normalization).

Results

Twenty-eight patients with adrenal CS were enrolled: 16 with adrenocortical carcinoma and 12 with benign disease. Osilodrostat was used in monotherapy in 22 patients and in combination with metyrapone in 6 cases. In those patients treated for longer than 4 weeks (n = 21), 66.7% were classified as responders (28.6% with complete response and 38.1% with partial response), and for those treated for longer than 12 weeks, the rate of response increased to 87.5% The use of osilodrostat as a nonfirst-line therapy (odds ratio 15.0, P = .010) was a predictor of response. Osilodrostat led to a significant decrease in systolic blood pressure and body weight (P < .05). Nine patients developed one or more adverse events and in 56% (n = 5) led to osilodrostat discontinuation.

Conclusion

Osilodrostat controls hypercortisolism in 66.7% of patients with adrenal CS treated for longer than 4 weeks and in 87.5% of cases treated for longer than 12 weeks, with a positive impact on blood pressure and body weight. Patients who received osilodrostat after other previous steroidogenesis inhibitors have a higher probability of response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cushing SyndromePyridinesHumansFemaleMaleMiddle AgedAdultTreatment OutcomeHydrocortisoneAgedAdrenal Cortex NeoplasmsMetyraponeDrug Therapy, CombinationAdrenocortical CarcinomaYoung AdultImidazoles

Stichwörter der Autor:innen

Cushing syndromeadrenal adenomaadrenocortical carcinomaosilodrostaturinary free cortisol

Substanzen

OsilodrostatHydrocortisonePyridinesMetyraponeImidazoles

Autor:innen und Institutionen

  • Endocrinology and Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid 28034, Spain.
  • Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid 28034, Spain.
  • Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg 97080, Germany.
  • Department of Medicine IV, LMU University Hospital, LMU Munich, Munich 81377, Germany.
  • Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metab…

ORCID-Profile: Marta Araujo-Castro, Irina Bancos, Mario Detomas, Martin Reincke, Barbara Altieri, Wilfredo Antonio Rivera Martínez

Zitieren

APA

Araujo-Castro, M., Bancos, I., Detomas, M., Reincke, M., Salehi, M., Lu, H., Altieri, B., Kroiss, M., Oettle, M., Guerrero-Pérez, F., Hanzu, F. A., García-Centeno, R., Gónzalez-Fernandez, L., Pasarón, M., Gracia Gimeno, P., Manzano Valero, L., Castro Luna, A., Irigaray Echarri, A., Ollero Garcia-Argullo, M. D., & Rivera Martínez, W. A. (2026). International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag115

Vancouver

Araujo-Castro M, Bancos I, Detomas M, Reincke M, Salehi M, Lu H, et al. International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag115

BibTeX
@article{AraujoCastro2026,
  author = {Araujo-Castro, Marta and Bancos, Irina and Detomas, Mario and Reincke, Martin and Salehi, Mahdi and Lu, Haibo and Altieri, Barbara and Kroiss, Markus and Oettle, Matthias and Guerrero-Pérez, Fernando and Hanzu, Felicia A and García-Centeno, Rogelio and Gónzalez-Fernandez, Laura and Pasarón, María and Gracia Gimeno, Paola and Manzano Valero, Lucía and Castro Luna, Ana and Irigaray Echarri, Ana and Ollero Garcia-Argullo, María Dolores and Rivera Martínez, Wilfredo Antonio},
  title = {International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag115}
}
Kostenlos starten →